Abstract
The purpose of the present study was to determine the responsiveness of airway vascular smooth muscle (AVSM) as assessed by airway mucosal blood flow (Qaw) to inhaled methoxamine (α1-agonist; 0.6-2.3 mg) and albuterol (β2-agonist; 0.2-1.2 mg) in healthy [n = 11; forced expiratory volume in 1 s, 92 ± 4 (SE) % of predicted] and asthmatic (n = 11, mean forced expiratory volume in 1 s, 81 ± 5%) adults. Mean baseline values for Qaw were 43.8 ± 0.7 and 54.3 ± 0.8 μl·min-1·ml-1 of anatomic dead space in healthy and asthmatic subjects, respectively (P < 0.05). After methoxamine inhalation, the maximal mean change in Qaw was -13.5 ± 1.0 μl·min-1·ml-1 in asthmatic and -7.1 ± 2.1 μl·min-1·ml-1 in healthy subjects (P < 0.05). After albuterol, the mean maximal change in Qaw was 3.0 ± 0.8 μl·min-1·ml-1 in asthmatic and 14.0 ± 1.1 μl·min-1·ml-1 in healthy subjects (P < 0.05). These results demonstrate that the contractile response of AVSM to α1-adrenoceptor activation is enhanced and the dilator response of AVSM to β2-adrenoceptor activation is blunted in asthmatic subjects.
| Original language | English |
|---|---|
| Pages (from-to) | 665-669 |
| Number of pages | 5 |
| Journal | Journal of Applied Physiology |
| Volume | 90 |
| Issue number | 2 |
| State | Published - Feb 15 2001 |
Fingerprint
Keywords
- Adrenergic agonists
- Asthma
- Bronchial blood flow
ASJC Scopus subject areas
- Physiology
- Endocrinology
- Orthopedics and Sports Medicine
- Physical Therapy, Sports Therapy and Rehabilitation
Cite this
Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects. / Brieva, Jorge; Wanner, Adam.
In: Journal of Applied Physiology, Vol. 90, No. 2, 15.02.2001, p. 665-669.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects
AU - Brieva, Jorge
AU - Wanner, Adam
PY - 2001/2/15
Y1 - 2001/2/15
N2 - The purpose of the present study was to determine the responsiveness of airway vascular smooth muscle (AVSM) as assessed by airway mucosal blood flow (Qaw) to inhaled methoxamine (α1-agonist; 0.6-2.3 mg) and albuterol (β2-agonist; 0.2-1.2 mg) in healthy [n = 11; forced expiratory volume in 1 s, 92 ± 4 (SE) % of predicted] and asthmatic (n = 11, mean forced expiratory volume in 1 s, 81 ± 5%) adults. Mean baseline values for Qaw were 43.8 ± 0.7 and 54.3 ± 0.8 μl·min-1·ml-1 of anatomic dead space in healthy and asthmatic subjects, respectively (P < 0.05). After methoxamine inhalation, the maximal mean change in Qaw was -13.5 ± 1.0 μl·min-1·ml-1 in asthmatic and -7.1 ± 2.1 μl·min-1·ml-1 in healthy subjects (P < 0.05). After albuterol, the mean maximal change in Qaw was 3.0 ± 0.8 μl·min-1·ml-1 in asthmatic and 14.0 ± 1.1 μl·min-1·ml-1 in healthy subjects (P < 0.05). These results demonstrate that the contractile response of AVSM to α1-adrenoceptor activation is enhanced and the dilator response of AVSM to β2-adrenoceptor activation is blunted in asthmatic subjects.
AB - The purpose of the present study was to determine the responsiveness of airway vascular smooth muscle (AVSM) as assessed by airway mucosal blood flow (Qaw) to inhaled methoxamine (α1-agonist; 0.6-2.3 mg) and albuterol (β2-agonist; 0.2-1.2 mg) in healthy [n = 11; forced expiratory volume in 1 s, 92 ± 4 (SE) % of predicted] and asthmatic (n = 11, mean forced expiratory volume in 1 s, 81 ± 5%) adults. Mean baseline values for Qaw were 43.8 ± 0.7 and 54.3 ± 0.8 μl·min-1·ml-1 of anatomic dead space in healthy and asthmatic subjects, respectively (P < 0.05). After methoxamine inhalation, the maximal mean change in Qaw was -13.5 ± 1.0 μl·min-1·ml-1 in asthmatic and -7.1 ± 2.1 μl·min-1·ml-1 in healthy subjects (P < 0.05). After albuterol, the mean maximal change in Qaw was 3.0 ± 0.8 μl·min-1·ml-1 in asthmatic and 14.0 ± 1.1 μl·min-1·ml-1 in healthy subjects (P < 0.05). These results demonstrate that the contractile response of AVSM to α1-adrenoceptor activation is enhanced and the dilator response of AVSM to β2-adrenoceptor activation is blunted in asthmatic subjects.
KW - Adrenergic agonists
KW - Asthma
KW - Bronchial blood flow
UR - http://www.scopus.com/inward/record.url?scp=0035146256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035146256&partnerID=8YFLogxK
M3 - Article
C2 - 11160067
AN - SCOPUS:0035146256
VL - 90
SP - 665
EP - 669
JO - Journal of Applied Physiology
JF - Journal of Applied Physiology
SN - 8750-7587
IS - 2
ER -